Medical Robotics Companies 2026: Market Size, Key Players and Regional Insights
Market size, 2025
Projected, 2026
Projected, 2027
Projected, 2035
CAGR, 2026–2035
Key Takeaways
- The global Medical Robotics market was USD 3,393.4 million in 2025 and is projected to reach USD 3,522.93 million in 2026, USD 3,657.6 million in 2027 and USD 4,937.58 million by 2035.
- That is a CAGR of 3.82% over 2026–2035, adding about USD 1,414.65 million in annual value between 2026 and 2035.
- The 2035 value is roughly 1.40 times the 2026 level, which points to steady, durable growth rather than a sudden spike.
- North America leads on installed base and procedure volume, while Asia-Pacific is expected to grow fastest.
- Intuitive Surgical and Stryker are growing at double-digit rates, while radiation, exoskeleton and consumer-robotics companies have been more volatile.
What Are Medical Robotics Companies?
Medical Robotics companies design, build and service robotic systems used in healthcare. Their products help clinicians operate, deliver radiation, rehabilitate patients and automate hospital workflows. The industry covers five main groups:
- Surgical robots: Intuitive Surgical (da Vinci), Stryker (Mako), Mazor Robotics (now part of Medtronic) and Hansen Medical (now part of Johnson & Johnson MedTech).
- Radiosurgery robots: Accuray (CyberKnife and Radixact).
- Rehabilitation and exoskeletons: Lifeward (formerly ReWalk Robotics), Ekso Bionics Holdings, Cyberdyne and Toyota.
- Pharmacy and hospital automation: ARxIUM, Aesynt, Kirby Lester and Aethon.
- Research and industrial technology providers: RIKEN, Fraunhofer, Yaskawa and iRobot (consumer robotics, included here as an adjacent case study).
How Big Is the Medical Robotics Industry in 2026?
The global Medical Robotics market is projected at USD 3,522.93 million in 2026, up from USD 3,393.4 million in 2025, which is growth of about 3.82%. The table below shows the forecast path.
| Year | Market Size (USD Million) | Note |
|---|---|---|
| 2025 | 3,393.40 | Base year |
| 2026 | 3,522.93 | First forecast year |
| 2027 | 3,657.60 | About +USD 134.67 million versus 2026 |
| 2035 | 4,937.58 | About +USD 1,414.65 million versus 2026 |
Growth is supported by rising minimally invasive surgery volumes, robotic orthopedics, ageing populations, reimbursement for rehabilitation devices, and hospital pharmacy automation. Recurring revenue from instruments, accessories and service contracts also adds stability.
Global Distribution of Medical Robotics Manufacturers by Country in 2026
No public registry counts every medical robotics manufacturer by country. The table below is a sample of the 17 organizations profiled in this article, so it shows where the industry is concentrated rather than giving a complete census.
| Country | Companies in Sample | Share of Sample | Organizations |
|---|---|---|---|
| United States | 9 | 52.9% | Intuitive Surgical, Stryker, Hansen Medical, Accuray, Ekso Bionics, Aesynt, Kirby Lester, Aethon, iRobot |
| Japan | 4 | 23.5% | Toyota, RIKEN, Yaskawa, Cyberdyne |
| Israel | 2 | 11.8% | Mazor Robotics, Lifeward (ReWalk) |
| Germany | 1 | 5.9% | Fraunhofer |
| Canada | 1 | 5.9% | ARxIUM |
Corporate restructuring has changed several identities. Mazor is part of Medtronic, Hansen Medical passed through Auris to Johnson & Johnson, Aesynt is part of Omnicell, Aethon is part of ST Engineering, ReWalk was renamed Lifeward, and iRobot became a wholly owned subsidiary of Shenzhen Picea Robotics after emerging from Chapter 11 in January 2026.
Growing Across Major Regions and Opportunities
Regional shares below come from third-party analyst estimates and are indicative only. Definitions of “medical robotics” differ between reports.
North America: Key Countries with Statistics
- Market position: analyst estimates put North America at roughly 38–40% of the global market, making it the largest region.
- United States: Stryker reports that over two-thirds of US knee procedures and over one-third of US hip procedures now use its Mako robot. Intuitive reported 18% growth in US general surgery procedures in 2025.
- Why it leads: a dense network of ambulatory surgery centers, established reimbursement, and the home markets of Intuitive, Stryker and Accuray.
- Canada: a smaller market, active in hospital automation, pharmacy robotics and clinical research.
Europe: Key Countries with Statistics
- Market position: approximately 27% of the global market by one regional split.
- Germany: the research and manufacturing hub, backed by Fraunhofer. Cyberdyne reported that Medical HAL Lower Limb Type sales grew mainly in Germany in fiscal 2025.
- United Kingdom, France, Italy and Spain: steady adopters of robotic orthopedic and soft-tissue surgery.
- Constraint: public hospital budgets and procurement cycles. Stryker described the European capital environment as slower.
Asia-Pacific: Key Countries with Statistics
- Market position: approximately 26% of the global market, and the fastest-growing region.
- Japan: a global centre for exoskeletons and rehabilitation robotics through Cyberdyne, Toyota, RIKEN and Yaskawa. Cyberdyne had 3,297 HAL and related units in operation at the end of March 2026.
- China: one report assigns China a 12% share of the global market and Japan 7%. Domestic surgical robot manufacturers are scaling quickly.
- India and South Korea: expanding robot-assisted surgery and hospital automation. Stryker named emerging markets, South Korea and Japan as drivers of its international growth.
Middle East & Africa: Key Countries with Statistics
- Market position: approximately 6% of the global market, building from a small base.
- UAE and Saudi Arabia: government investment and medical tourism are driving adoption. IMARC reports that the UAE holds a 44.6% share of the GCC surgical robots market.
- Distribution example: Lifeward expanded ReWalk Personal Exoskeleton distribution into the UAE, Mexico and Thailand through a partner-led model.
- South Africa: the main sub-Saharan market, led by private hospital groups.
Top Medical Robotics Companies: Headquarters, Revenue, CAGR and Geographic Presence
Revenue figures are company-wide, not medical-robotics-only, so some exceed the market size above. Growth is shown as the latest reported change or an approximate multi-year CAGR where stated.
| Company | Headquarters | Latest Reported Revenue (Company-Wide) | CAGR / Growth | Geographic Presence | Key Highlight | Holding Type |
|---|---|---|---|---|---|---|
| Intuitive Surgical | Sunnyvale, California, USA | ~USD 10.06 billion (2025) | +21% in 2025; ~18% CAGR 2020–2025 | North America, Europe, Asia-Pacific, Middle East | 3.15 million da Vinci procedures in 2025; 870 da Vinci 5 placements | Public (Nasdaq: ISRG) |
| Mazor Robotics | Caesarea, Israel | Within Medtronic | Not separately disclosed | Global via Medtronic | Mazor X spine-surgery platform | Acquired by Medtronic (2018) |
| Stryker | Kalamazoo, Michigan, USA | Above USD 25 billion (2025) | +10.3% organic in 2025; ~12% CAGR 2020–2025 | North America, Europe, Asia-Pacific, emerging markets | 3,000+ Mako systems installed worldwide | Public (NYSE: SYK) |
| Hansen Medical | Mountain View, California, USA | Not separately reported | Not applicable | Via Johnson & Johnson MedTech | Pioneer of robotic vascular catheter systems | Acquired by Auris (2016); Auris by J&J (2019) |
| Lifeward (ReWalk) | Yokneam Ilit, Israel / Hudson, USA | USD 5.1 million (Q4 2025) | -33% year over year (Q4 2025) | US, Europe, Mexico, Thailand, UAE | ReWalk Personal Exoskeleton with Medicare Advantage coverage | Public (Nasdaq: LFWD) |
| Toyota | Toyota City, Aichi, Japan | ~JPY 48 trillion group revenue (FY to Mar 2025) | Medical robotics not disclosed | Global | Welwalk walking-training rehabilitation robot | Public (TSE: 7203) |
| Accuray | Madison, Wisconsin, USA | USD 401.9 million (FY2026) | -12% in FY2026 | North America, Europe, Asia-Pacific, Middle East | CyberKnife, Radixact and the new Accuray Stellar | Public (Nasdaq: ARAY) |
| Kirby Lester | Lake Forest, Illinois, USA | Not separately reported | Not applicable | North America and international pharmacy markets | Pharmacy counting and dispensing automation | Part of a larger pharmacy-automation group |
| Ekso Bionics Holdings | San Rafael, California, USA | USD 12.8 million (2025) | -29% in 2025 | North America, Europe, Asia-Pacific | Ekso Indego Personal; reimbursement-led strategy | Public (Nasdaq: EKSO) |
| Aesynt | Pittsburgh, Pennsylvania, USA | Within Omnicell | Not separately disclosed | North America, Europe | Medication-management and IV-compounding automation | Acquired by Omnicell (2016) |
| ARxIUM | Winnipeg, Manitoba, Canada | Not publicly disclosed | Not publicly disclosed | North America, Europe, Asia-Pacific | RIVA IV-compounding robot | Private |
| Aethon | Pittsburgh, Pennsylvania, USA | Within ST Engineering | Not separately disclosed | Primarily US hospitals | TUG autonomous hospital delivery robots | Subsidiary of ST Engineering |
| RIKEN | Wako, Saitama, Japan | Not applicable (publicly funded) | Not applicable | Japan and international collaborations | Nursing-care and assistive robotics research | National research institute |
| Yaskawa Electric | Kitakyushu, Fukuoka, Japan | JPY 542.1 billion (FY to Feb 2026) | +0.8% in FY2025 | Asia, Europe, Americas | Industrial robot leader supplying lab, pharma and medical automation | Public (TSE: 6506) |
| Fraunhofer | Munich, Germany | Not applicable (non-profit) | Not applicable | Germany, Europe, global partnerships | Applied research in care, surgical and rehabilitation robotics | Non-profit research organization |
| iRobot | Bedford, Massachusetts, USA | USD 681.8 million (2024) | -23.4% in 2024 | North America, Europe, Asia | Emerged from Chapter 11 in January 2026 | Private, owned by Shenzhen Picea Robotics |
| Cyberdyne | Tsukuba, Ibaraki, Japan | JPY 3,846 million (FY to Mar 2026) | -12.3% in FY2025; ~15% CAGR FY2021–FY2026 | Japan, Europe, Americas, Asia-Pacific | 3,297 HAL and related units in operation | Public (TSE Growth: 7779) |
Latest Company Updates in 2026
- Intuitive Surgical: 2025 revenue of about USD 10.06 billion (+21%), 1,721 da Vinci placements and about 3,153,000 procedures (+18%). Management expects da Vinci procedures to grow approximately 13% to 15% in 2026.
- Stryker: sales above USD 25 billion in 2025 with 10.3% organic growth. Shoulder applications launch on Mako 4 in mid-2026, and tariff impacts are expected to be about USD 400 million.
- Accuray: fiscal 2026 revenue of USD 401.9 million (-12%). Product revenue fell 27% while service revenue rose 4% to USD 229.2 million. A new CEO was appointed and Accuray Stellar was introduced.
- Lifeward: shareholder approval for the Oramed transaction, with up to USD 47 million in funding, plus an agreement to acquire a powered upper-body exoskeleton technology. Aetna, Humana and UnitedHealthcare added Medicare Advantage coverage for ReWalk Personal.
- Ekso Bionics: 2025 revenue of USD 12.8 million (-29%) and year-end cash of USD 1.17 million. More than 50 people were identified as potentially eligible for Ekso Indego Personal reimbursement.
- Cyberdyne: fiscal 2025 revenue of JPY 3,846 million (-12.3%) with a narrower operating loss, and 3,297 units in operation.
- Yaskawa: revenue of JPY 542.1 billion (+0.8%) for the year ended February 2026.
- iRobot: emerged from Chapter 11 in January 2026 under Shenzhen Picea Robotics ownership.
- Mazor, Hansen Medical, Aesynt, Aethon, Kirby Lester, Toyota, RIKEN, Fraunhofer, ARxIUM: no standalone 2026 announcements or financial disclosures were identified, so none are claimed here.
High-End and Specialty Medical Robotics Manufacturers
| Specialty | Leading Names | What Sets Them Apart |
|---|---|---|
| Multispecialty soft-tissue surgery | Intuitive Surgical | Instruments and accessories revenue rose 19% to about USD 6.02 billion in 2025, alongside about USD 2.47 billion in systems revenue. |
| Orthopedic robotics | Stryker, Mazor (Medtronic) | Stryker’s global Mako utilization is about 50% for knees and over 20% for hips, leaving room for growth. |
| Radiation oncology | Accuray | CyberKnife and Radixact with a growing service revenue base. |
| Exoskeletons and neurorehabilitation | Lifeward, Ekso Bionics, Cyberdyne, Toyota | Adoption depends on clinical evidence and payer coverage. |
| Pharmacy and hospital logistics | ARxIUM, Aesynt, Kirby Lester, Aethon | Return on investment from fewer medication errors and labor savings. |
| Research and enabling technology | RIKEN, Fraunhofer, Yaskawa | Seed technologies that startups and industrial firms later commercialize. |
Opportunities for Startups and Emerging Players (2026)
With a projected 3.82% CAGR, growth will favor companies that win on evidence, reimbursement and service rather than on hardware alone. Six openings stand out:
- Ambulatory surgery centers: one forecast calls ASCs the fastest-growing end-user segment in robotic surgery. Smaller, modular, lower-cost systems suit these buyers.
- Reimbursed rehabilitation: Lifeward’s Medicare Advantage gains show that payer coverage unlocks sales.
- Asia-Pacific and Gulf expansion: regional partners and distributors matter, and Lifeward’s partner-led model is a template for capital-efficient entry.
- Software and AI: procedure guidance, analytics and training simulation can be sold to hospitals that already operate robots.
- Service and refurbishment: Accuray’s service revenue grew while product sales fell, and Intuitive placed 42 refurbished da Vinci Xi systems in 2025.
- Pharmacy and hospital automation: less crowded than surgery, with clear return-on-investment arguments.
Risks: long regulatory timelines, hospital capital-budget delays, tariffs, and thin financing. Ekso Bionics ended 2025 with only USD 1.17 million in cash, so a funded route to reimbursement and distribution is essential.
Frequently Asked Questions
What are Medical Robotics companies?
They are businesses that build and service robotic systems for surgery, radiation therapy, rehabilitation, pharmacy compounding and hospital logistics, including Intuitive Surgical, Stryker, Accuray, Lifeward, Ekso Bionics and Cyberdyne.
How big is the Medical Robotics industry in 2026?
The market is projected at USD 3,522.93 million in 2026, rising to USD 3,657.6 million in 2027 and USD 4,937.58 million by 2035.
What is the CAGR of the Medical Robotics market?
The market is forecast to grow at a CAGR of 3.82% during 2026–2035.
Which region leads the Medical Robotics market?
North America leads, with analyst estimates of roughly 38–40% share. Asia-Pacific is expected to grow fastest.
Conclusion
The global Medical Robotics market grew from USD 3,393.4 million in 2025 to a projected USD 3,522.93 million in 2026, and is forecast to reach USD 4,937.58 million by 2035 at a 3.82% CAGR. That is a steady growth path, with about USD 1,414.65 million in added annual value between 2026 and 2035.
The strongest results come from companies with large installed bases and recurring revenue, such as Intuitive Surgical and Stryker. Radiation, exoskeleton and consumer-robotics companies are more volatile, and several historic names now sit inside larger groups.
For companies and startups, the most credible openings are ambulatory surgery systems, reimbursed rehabilitation devices, software, services, regional distribution and pharmacy automation. Firms that combine clinical evidence, reimbursement access and dependable service are best placed to benefit through 2035.